Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MagicTouch SCB is a sirolimus drug-coated balloon (SCB) catheter designed for the treatment of coronary artery disease, specifically targeting in-stent restenosis (ISR), small vessel disease, bifurcation lesions, and de-novo coronary lesions. Developed by Concept Medical, it utilizes proprietary Nanolutè technology to encapsulate sub-micron sized sirolimus particles within a biocompatible phospholipid carrier. This allows for rapid and effective transfer of sirolimus into the vessel wall during balloon inflation—achieving homogeneous drug distribution with minimal downstream exposure. The released sirolimus inhibits neointimal proliferation by acting as an mTOR inhibitor, reducing smooth muscle cell proliferation and thus preventing restenosis. The device is CE marked and has extensive commercial use in Europe, Asia, and the Middle East; it is currently under clinical investigation in the United States with multiple ongoing pivotal trials[1][2][3][5][7][8][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MagicTouch SCB.